{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T07:46:31Z","timestamp":1777880791872,"version":"3.51.4"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archivos de la Sociedad Espa\u00f1ola de Oftalmolog\u00eda (English Edition)"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.oftale.2026.502558","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T16:41:20Z","timestamp":1776444080000},"page":"502558","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Photodynamic therapy in neovascular age-related macular degeneration: Past or present in the era of second-generation anti-VEGF agents?"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8745-3464","authenticated-orcid":false,"given":"J.I.","family":"Fern\u00e1ndez-Vigo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Gallego-Pinazo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Montero Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Arias-Barquet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.J.","family":"Ar\u00e9valo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Garc\u00eda-Layana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.oftale.2026.502558_bib0005","first-page":"198","article-title":"Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2","volume":"119","author":"Bressler","year":"2001","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.oftale.2026.502558_bib0010","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.2147\/OPTH.S464371","article-title":"Verteporfin photodynamic therapy for the treatment of chorioretinal conditions: a narrative review","volume":"18","author":"Garg","year":"2024","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.oftale.2026.502558_bib0015","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1001\/jamaophthalmol.2020.2443","article-title":"Comparison of ranibizumab with or without verteporfin photodynamic therapy for polypoidal choroidal vasculopathy: the EVEREST II Randomized Clinical Trial","volume":"138","author":"Lim","year":"2020","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.oftale.2026.502558_bib0020","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1159\/000518235","article-title":"Efficacy and safety of intravitreal aflibercept treat and extend for polypoidal choroidal vasculopathy in the ATLANTIC study: a randomized clinical trial","volume":"245","author":"Silva","year":"2022","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.oftale.2026.502558_bib0025","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1001\/jamaophthalmol.2025.5098","article-title":"Aflibercept 8 mg in polypoidal choroidal vasculopathy: post hoc analysis of the PULSAR randomized clinical trial","volume":"144","author":"Lee","year":"2026","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.oftale.2026.502558_bib0030","unstructured":"Lai TYY, Cheung CMG, Yamashiro K, et al. Faricimab for polypoidal choroidal vasculopathy: 1-year results from the phase IIIb\/IV SALWEEN trial. Presented at: EURETINA 2025; Paris, France."},{"key":"10.1016\/j.oftale.2026.502558_bib0035","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1001\/jamaophthalmol.2018.1804","article-title":"Efficacy and safety of intravitreal aflibercept for polypoidal choroidal vasculopathy in the PLANET study: a randomized clinical trial","volume":"136","author":"Lee","year":"2018","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.oftale.2026.502558_bib0040","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.ophtha.2017.11.019","article-title":"Polypoidal choroidal vasculopathy: definition, pathogenesis, diagnosis, and management","volume":"125","author":"Cheung","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oftale.2026.502558_bib0045","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1001\/jamaophthalmol.2025.0250","article-title":"Aflibercept with vs. without reduced-fluence photodynamic therapy for polypoidal choroidal vasculopathy: a randomized clinical trial","volume":"143","author":"Chong","year":"2025","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.oftale.2026.502558_bib0050","first-page":"1","article-title":"Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: meta-analysis of 2-year safety results in three randomized clinical trials","volume":"24","author":"Azab","year":"2004","journal-title":"Retina"}],"container-title":["Archivos de la Sociedad Espa\u00f1ola de Oftalmolog\u00eda (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173579426001027?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173579426001027?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:22:21Z","timestamp":1777594941000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2173579426001027"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":10,"alternative-id":["S2173579426001027"],"URL":"https:\/\/doi.org\/10.1016\/j.oftale.2026.502558","relation":{},"ISSN":["2173-5794"],"issn-type":[{"value":"2173-5794","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Photodynamic therapy in neovascular age-related macular degeneration: Past or present in the era of second-generation anti-VEGF agents?","name":"articletitle","label":"Article Title"},{"value":"Archivos de la Sociedad Espa\u00f1ola de Oftalmolog\u00eda (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.oftale.2026.502558","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.oftal.2026.502558","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Espa\u00f1a, S.L.U. on behalf of Sociedad Espa\u00f1ola de Oftalmolog\u00eda.","name":"copyright","label":"Copyright"}],"article-number":"502558"}}